NCT06654700View on ClinicalTrials.gov

Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Recombinant Zoster Vaccine (CHO Cell)

0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection

Trial Locations (1)

450016

Henan Center for Diseases Control and Prevention, Zhengzhou

Sponsors
All Listed Sponsors
lead

MAXVAX Biotechnology Limited Liability Company

INDUSTRY

NCT06654700 - Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell). | Biotech Hunter | Biotech Hunter